Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

PolandBack to Poland

Clinical trials in Bydgoszcz – page 24

723 clinical trials in Bydgoszcz, Poland across 6 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

PolandOur site in PolandBadaniaKliniczne.pl(opens in a new tab)
Bydgoszcz at a glance
723
clinical trials
  • Research sites6
Type of trial
Recruitment status
Quick filters

723 trials in Bydgoszcz

Open in trial search

Plasma cell myeloma

Not yet recruiting

Ramantamig (JNJ-79635322) with drug combination versus standard therapy in newly diagnosed multiple myeloma patients not eligible for stem cell transplant

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Parkinson's disease

Not yet recruiting

A Randomized Trial of lu af28996 dh1 to Reduce Motor Fluctuations in Adults with Parkinson’s Disease

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Sponsor:H. Lundbeck A/S

Adenocarcinoma pancreas

Not yet recruiting

First‑line Study of RMC‑9805 with Investigator’s Choice Chemotherapy Drug Combination vs Chemotherapy Alone in Patients with Metastatic KRAS G12D‑Mutated Pancreatic Adenocarcinoma

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:(2S)-2-CYCLOPENTYL-2-[(5S)-2-[(2R,3R)-3-CYCLOPROPYL-1-METHYLAZIRIDINE-2-CARBONYL]-2,7-DIAZASPIRO[4.4]NONAN-7-YL]-N-[(6S,8S,14S)-21-[5-(4-CYCLOPROPYLPIPERAZIN-1-YL)-2-[(1S)-1-METHOXYETHYL]PYRIDIN-3-YL]-18,18-DIMETHYL-9,15-DIOXO-22-(2,2,2-TRIFLUOROETHYL)-5,16-DIOXA-2,10,22,28-TETRAZAPENTACYCLO[18.5.2.12,6.110,14.023,27]NONACOSA-1(26),20,23(27),24-TETRAEN-8-YL]ACETAMIDE
  • Sponsor:Revolution Medicines Inc.

Heart failure with reduced ejection fraction

Not yet recruiting

Evaluating the efficacy and safety of CRD-4730 in patients with heart failure with reduced ejection fraction

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Crd-4730
  • Sponsor:Cardurion Pharmaceuticals Inc.

Plasma cell myeloma

Not yet recruiting

Teclistamab drug combination versus daratumumab and lenalidomide in MRD‑positive multiple myeloma patients after stem cell transplant

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Polish Myeloma Consortium

Plasma cell myeloma

Not yet recruiting

Reduced vs Standard Dose Belantamab Mafodotin with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Phase II MRD‑Guided Study

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Belantamab Mafodotin
  • Sponsor:Polish Myeloma Consortium

Systemic scleroderma

Not yet recruiting

Safety and Efficacy of MTX-474 in Adults with Diffuse Cutaneous Systemic Sclerosis (dcSSc) – A Phase 2 Randomized, Double‑Blind, Placebo‑Controlled Study

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Glucose Monohydrate
  • Sponsor:Mediar Therapeutics Inc.

Chronic lymphocytic leukaemia+1

Not yet recruiting

Study of venetoclax plus rituximab in adult patients with relapsed chronic lymphocytic leukemia (CLL) in Poland

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Uniwersytet Medyczny W Lublinie

Major depression

Not yet recruiting

Long‑Term Safety, Tolerability and Efficacy of Azetukalner in Patients with Major Depressive Disorder

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Azetukalner
  • Sponsor:Xenon Pharmaceuticals Inc.

Interstitial lung disease+2

Not yet recruiting

Long‑term Safety and Tolerability of Admilparant in Adults with Idiopathic or Progressive Pulmonary Fibrosis

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:ADMILPARANT
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Chronic lymphocytic leukaemia+1

Not yet recruiting

Safety and efficacy of venetoclax, obinutuzumab and daratumumab in adult patients with relapsed chronic lymphocytic leukemia

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Uniwersytet Medyczny W Lublinie

Pulmonary fibrosis

Not yet recruiting

A study to evaluate the effectiveness and safety of admilparant in patients with progressive pulmonary fibrosis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:ADMILPARANT
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Other cities in Poland

The busiest research cities in the country

All 239 cities in Poland

Clinical research in Bydgoszcz

What the registry says about research in the country

01 Respiratory & Infectious Diseases

Innovative clinical trials focusing on respiratory syncytial virus (RSV) and pneumococcal infections in both adults and children. Studies include vaccine development for multiple age groups and assessment of immune responses.

  • RSV and Metapneumovirus Prevention
  • Pneumococcal Vaccine Development
  • COPD Treatment Innovation

Research emphasizes preventive measures and vaccine efficacy across different age groups.

02 Neurological Disorders

Groundbreaking research into neurodegenerative conditions, with particular focus on early intervention strategies for Alzheimer's and Parkinson's disease treatment approaches.

  • Early Alzheimer's Disease
  • Parkinson's Disease Therapeutics
  • Myasthenia Gravis Management

Studies aim to slow disease progression and improve patient outcomes.

03 Autoimmune & Inflammatory Conditions

Comprehensive trials examining new treatments for various inflammatory disorders, including psoriasis, arthritis, and inflammatory bowel diseases.

  • Psoriatic Arthritis
  • Crohn's Disease
  • Atopic Dermatitis

Focus on developing targeted therapies for chronic inflammatory conditions.

Back to PolandAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.